4HQQ

Crystal structure of RV144-elicited antibody CH58


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.183 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2.

Liao, H.X.Bonsignori, M.Alam, S.M.McLellan, J.S.Tomaras, G.D.Moody, M.A.Kozink, D.M.Hwang, K.K.Chen, X.Tsao, C.Y.Liu, P.Lu, X.Parks, R.J.Montefiori, D.C.Ferrari, G.Pollara, J.Rao, M.Peachman, K.K.Santra, S.Letvin, N.L.Karasavvas, N.Yang, Z.Y.Dai, K.Pancera, M.Gorman, J.Wiehe, K.Nicely, N.I.Rerks-Ngarm, S.Nitayaphan, S.Kaewkungwal, J.Pitisuttithum, P.Tartaglia, J.Sinangil, F.Kim, J.H.Michael, N.L.Kepler, T.B.Kwong, P.D.Mascola, J.R.Nabel, G.J.Pinter, A.Zolla-Pazner, S.Haynes, B.F.

(2013) Immunity 38: 176-186

  • DOI: 10.1016/j.immuni.2012.11.011
  • Primary Citation of Related Structures:  4HPO, 4HPY

  • PubMed Abstract: 
  • The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of ...

    The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope variable regions 1 and 2 (V1-V2). Genetic analysis of trial viruses revealed increased vaccine efficacy against viruses matching the vaccine strain at V2 residue 169. Here, we isolated four V2 monoclonal antibodies from RV144 vaccinees that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV-1-infected CD4(+) T cells. Crystal structures of two of the V2 antibodies demonstrated that residue 169 can exist within divergent helical and loop conformations, which contrasted dramatically with the β strand conformation previously observed with a broadly neutralizing antibody PG9. Thus, RV144 vaccine-induced immune pressure appears to target a region that may be both sequence variable and structurally polymorphic. Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options.


    Organizational Affiliation

    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. hliao@duke.edu




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
CH58 Fab heavy chain
H
231N/AN/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
CH58 Fab light chain
L
216N/AN/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.183 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 62.949α = 90.00
b = 70.440β = 90.00
c = 135.825γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
HKL-2000data scaling
SERGUIdata collection
PHENIXrefinement
HKL-2000data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-02-06
    Type: Initial release